Key result
Valve-in-valve TAVI linked to 0% in-hospital mortality versus redo-AVR for degenerated bioprostheses.
Why the study?
The comparative morbidity and mortality outcomes of redo aortic valve replacement versus valve-in-valve TAVI for failing bioprosthetic valves were unclear.
Does valve-in-valve TAVI reduce morbidity and mortality compared to redo-AVR in patients with a degenerated aortic bioprosthesis?
Comparison
Redo aortic valve replacement versus valve-in-valve trans-catheter aortic valve implantation
Design
Multicenter UK retrospective propensity score matched cohort study
Follow-up
6 years
Authors
Loading...
May support valve-in-valve TAVI to lower in-hospital mortality in observational cohorts; leaves open randomized confirmation before practice change.
Observational (n=1,322)
Yes
Does valve-in-valve TAVI reduce morbidity and mortality compared to redo-AVR in patients with a degenerated aortic bioprosthesis?
Absolute Event Rate: 0% vs 7.2%
p-value: p=0.002
Valve-in-valve TAVI offers superior early safety and lower in-hospital mortality compared to redo-AVR for degenerated bioprostheses, with comparable mid-term survival.
Gatta et al. (2023) conducted an observational in Degenerated aortic bioprosthesis (n=1,322). Valve-in-valve trans-catheter aortic valve implantation (TAVI) vs. Redo aortic valve replacement (redo-AVR) was evaluated on In-hospital mortality (p=0.002). Valve-in-valve trans-catheter aortic valve implantation was associated with 0% in-hospital mortality compared to 7.2% for redo aortic valve replacement in patients with a degenerated bioprosthesis.